ERBB2 and breast carcinoma: Breast cancer MDA-MB-231 (TN) and ovarian cancer SK-OV-3 cells were used to develop the model, and breast cancer SK-BR-3 (HER2+) to test the response to exposure to a small-molecule receptor Tyr kinase (RTK) inhibitor, Lapatinib.